Articles tagged with 'Export-TopNews' & 'Export-LatestNews' & 'only-PressPage' | Bayer

Newsroom Bayer (Export-TopNews,Export-LatestNews,only-PressPage)

2022
November
29,
2022
| 10:59 AM Europe/Amsterdam
Financial support for the Chernihiv Medical Center of Modern Oncology and the Romodanov Institute of Neurosurgery / The donation goes to UNITED24, the main platform for charitable donations to reconstruct Ukraine  ...
Read more
November
22,
2022
| 14:00 PM Europe/Amsterdam
New clinical data for the development compound gadoquatrane, a novel MRI contrast agent, presented at RSNA 2022 / Three new partnerships, AI app accelerator program and pipeline updates to be featured / Collaboration agreements signed to expand offer...
Read more
November
11,
2022
| 14:52 PM Europe/Amsterdam
Recommendation is based on the Phase III study FIREFLEYE and data from the follow-up study FIREFLEYE NEXT / Retinopathy of prematurity (ROP) can lead to severe visual impairment and blindness / Bayer will apply for a patent term extension for the pat...
Read more
November
10,
2022
| 08:59 AM Europe/Amsterdam
Targenomix, a spin-off of the Max Planck Institute for Molecular Plant Physiology, will contribute to Bayer’s Crop Science R&D pipeline by continuing to deliver novel systems biology approaches for innovative crop protection discovery / Targenomix wi...
Read more
November
09,
2022
| 13:30 PM Europe/Amsterdam
San Diego – November 9, 2022 – Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune diso...
Read more
November
08,
2022
| 10:01 AM Europe/Amsterdam
....
Read more
November
08,
2022
| 07:30 AM Europe/Amsterdam
Group sales increase by 5.7 percent (Fx & portfolio adj.) to 11.281 billion euros  / EBITDA before special items rises by 17.3 percent to 2.451 billion euros / Crop Science achieves strong sales gains – sales also up at Pharmaceuticals and Consumer H...
Read more
November
05,
2022
| 06:59 AM Europe/Amsterdam
Aflibercept 8 mg maintained 16-week dosing intervals in up to 89% of patients with as few as 5 injections until week 48 / Aflibercept 8 mg demonstrated non-inferior vision gains to Eylea® (aflibercept 2 mg) with 83% of patients with neovascular (wet)...
Read more
November
03,
2022
| 13:59 PM Europe/Amsterdam
California-based NuCicer has developed chickpeas with 75 percent more protein than conventional varieties, unlocking the potential of chickpea protein to become a scalable, affordable foundation for a sustainable plant-based future  / NuCicer’s techn...
Read more
October
26,
2022
| 12:00 PM Europe/Amsterdam
FIDELITY: Late-breaking data from pooled, post-hoc analysis will provide new insights into the efficacy and safety of Kerendia in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) who have sustained an acute change in estimated glo...
Read more
October
26,
2022
| 09:00 AM Europe/Amsterdam
The newest LifeHub in the Bayer network will connect the company more closely to the German innovation ecosystem of scientists, researchers, decision makers, and entrepreneurs / Focus lies on dialogue and innovation through open approaches that contr...
Read more
October
25,
2022
| 08:28 AM Europe/Amsterdam
The REALISE study explored symptom burden and impact of menopause symptoms in women across multiple countries, and the views of their treating physicians.  / This study confirmed vasomotor symptoms (VMS) are considered the most common and distressing...
Read more
October
20,
2022
| 08:29 AM Europe/Amsterdam
Bayer, together with the Bill & Melinda Gates Foundation, are jointly funding pre-clinical research in the area of novel non-hormonal contraception / This collaboration with the Bill & Melinda Gates Foundation will contribute to expanding access to c...
Read more
October
18,
2022
| 12:59 PM Europe/Amsterdam
Ginkgo Bioworks becomes a multi-year strategic partner with Bayer to develop biological solutions in areas such as nitrogen optimization, carbon sequestration, and next generation crop protection / Open Innovation Sourcing is expected to accelerate B...
Read more
October
17,
2022
| 09:00 AM Europe/Amsterdam
Study plans to investigate elinzanetant as non-hormonal treatment for vasomotor symptoms caused by endocrine therapy in breast cancer patients  / Elinzanetant is an innovative non-hormonal development compound in development for the treatment of vaso...
Read more
October
17,
2022
| 09:00 AM Europe/Amsterdam
Fields of Opportunity event on Bayer ForwardFarm on October 17, 2022 puts a spotlight on the company’s industry-leading solutions to increase sustainable food production / Board member Rodrigo Santos calls for a new approach to agriculture and for cl...
Read more
October
14,
2022
| 09:30 AM Europe/Amsterdam
Mirena® (52mg LNG IUS), Bayer’s long-acting reversible intrauterine system, received regulatory approval in the European Workshare Procedure for up to eight years in contraception, now offering the longest contraceptive duration of use for any hormon...
Read more
October
12,
2022
| 13:30 PM Europe/Amsterdam
Tavros to receive $17.5M upfront, up to $430.5M in milestone payments for initial four programs, and certain royalties over agreement term / Vividion will have rights to opt-in to up to five more targets for up to $482M in additional payments /Partne...
Read more
October
05,
2022
| 14:00 PM Europe/Amsterdam
Business to continue operations as an independent company called Envu...
Read more
September
26,
2022
| 09:00 AM Europe/Amsterdam
Approval is based on the Phase III study FIREFLEYE and data from the follow-up study FIREFLEYE NEXT / Retinopathy of prematurity (ROP) can lead to severe visual impairment and blindness / With ROP, Eylea® is now approved for six indications in Japan ...
Read more
September
20,
2022
| 11:45 AM Europe/Amsterdam
New post-hoc analyses from the prespecified pooled analysis FIDELITY will provide insights into the effects of finerenone on kidney and cardiovascular outcomes by use of glucagon-like peptide-1 receptor agonists (GLP-1RA) at baseline, as well as by b...
Read more
September
11,
2022
| 10:15 AM Europe/Amsterdam
Consistent benefits were also seen in other patient-relevant endpoints, including all-cause and prostate cancer-related death and cumulative incidence of adverse events (AEs) of special interest...
Read more
September
08,
2022
| 14:59 PM Europe/Amsterdam
Aflibercept 8 mg meets primary endpoints in two global pivotal studies in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) achieving non-inferior improvements in best corrected visual acuity to Eylea® (aflibe...
Read more
September
02,
2022
| 10:15 AM Europe/Amsterdam
U.S. Food and Drug Administration (FDA) granted label update for Kerendia™ (finerenone) to include findings from the Phase III FIGARO-DKD cardiovascular (CV) outcomes study in patients with chronic kidney disease (CKD) associated with type 2 diabetes...
Read more
September
01,
2022
| 16:00 PM Europe/Amsterdam
Succeeds Fei-Fei Li, who stepped down at the end of August...
Read more
August
30,
2022
| 14:00 PM Europe/Amsterdam
In prostate cancer, a key therapeutic area for Bayer, new patient-relevant data from the ARASENS Phase III study in metastatic hormone-sensitive prostate cancer (mHSPC) will be showcased, as well as data from the RALU study comprising real-world evid...
Read more
August
29,
2022
| 09:24 AM Europe/Amsterdam
Data from FIDELITY, a prespecified pooled analysis of the Phase III FIDELIO-DKD and FIGARO-DKD studies, highlight the potential of Kerendia™ (finerenone) to reduce the incidence of sudden cardiac death / While in the overall FIDELITY population, the ...
Read more
August
28,
2022
| 09:14 AM Europe/Amsterdam
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke events in patients with atrial fibrillation as well as patients with a non-cardioembolic ischemic stroke or high-ris...
Read more
August
23,
2022
| 08:05 AM Europe/Amsterdam
National Agency for Safety of Medicines and Health Products (ANSM) and French Ethics Committee approve protocol for trial expected to begin in Q4 2022 ...
Read more
August
22,
2022
| 09:00 AM Europe/Amsterdam
Late-breaking data from a new exploratory analysis of FIDELITY investigating causes of mortality in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) treated with Kerendia™ (finerenone) or placebo / New Phase IIb data from PACIFIC ...
Read more